Список проголосовавших за комментарий " Sector Summary: The Healthcare sector (-0.24%) is trading lower today, lagging the S&P 500 (0.00%)<strong><span style="color:#228822;">Gainers on news:</span></strong><br/> <ul><li>Threshold Pharma (<strong>THLD</strong> +18.82%) will merge with Molecular Templates in an all-stock transaction; Longitude Capital will invest $20 mln at the close of the transaction, including the receipt of additional equity financing commitments of $20 mln</li><li>AveXis (<strong>AVXS</strong> +17.35%) misses by $0.19; reports topline results from the Phase 1 trial of AVXS-101 in SMA Type 1</li><li>Arbutus Biopharma (<strong>ABUS</strong> +17.54%) licenses to Alexion Pharmaceuticals (ALXN) its proprietary lipid nanoparticle technology for exclusive use in one of Alexion's rare disease programs</li></ul><strong><span style="color:#ff0000;">Decliners on news:</span></strong><br/> <ul><li>Northwest Biotherapeutics (<strong>NWBO</strong> -33.15%) commences $7.5 mln direct offering of common stock at $0.26/share</li><li>Editas Medicine (<strong>EDIT</strong> -7.87%) prices offering of 4 mln shares of common stock at $22.50 per share</li><li>Zosano Pharma (<strong>ZSAN</strong> -4.94%) prices 17,000,000 share offering at $1.50/share</li></ul><strong><span style="color:#228822;">Gainers on earnings:</span></strong><br/> <ul><li>BioDelivery Sciences (<strong>BDSI</strong> +1.25%) misses by $0.06, misses on revs</li><li>BioTime (<strong>BTX</strong> +5.81%) reports Q4 EPS of ($0.05) vs ($0.15) last year; revs -25.9% y/y to $1.08 mln</li><li>Mannkind (<strong>MNKD</strong> +6.76%) reports Q4 (Dec) results, beats on revs</li></ul><strong><span style="color:#ff0000;">Decliners on earnings:</span></strong><br/> <ul><li>Innocell (<strong>INNL</strong> -26.5%) reports Q4 results; 'continues to explore strategic options'</li><li>ChromaDex (<strong>CDXC</strong> -10.13%) reported Q4 EPS of ($0.06) vs ($0.01) single est; co reported Q4 sales of +29% YoY to $5.6 mln (no ests).</li><li>Calithera Biosciences (<strong>CALA</strong> -9.49%) reports Q4 GAAP EPS of ($0.45), vs the ($0.48) Capital IQ Consensus Estimate</li></ul><strong>Upgrades/Downgrades:</strong><br/> <ul><li>Proteon Therapeutics (<strong>PRTO</strong> -7.14%) H.C. Wainwright Downgraded to NEUTRAL (from Buy) — Price Target: 3 (from 18)</li><li>Neos Therapeutics (<strong>NEOS</strong> -4.61%) downgraded to Neutral from Buy at UBS</li><li>Patheon (<strong>PTHN</strong> -1.48%) Robert W. Baird Downgraded to NEUTRAL (from Outperform)